visited Yinfeng Biological Group for investigation.
Release time:
2022-08-23

On August 18, Zhang Kun, Deputy Minister of the United Front Work Department of the Shandong Provincial Party Committee and Secretary of the Party Group of the Provincial Federation of Industry and Commerce, Yu Ling, Secretary-General of the Shandong Federation of Industry and Commerce, and Ma Ying, Honorary Chairman of Qilu Real Estate Co., Ltd., visited Yinfeng Biological Group for investigation.

Zhang Kun and his entourage successively visited the "Infinite Life Plan" Science Museum and the "Life Extension Plan" exhibition hall, as well as the virtual anatomy test center of Shandong Yinfeng Jinzheng Judicial Appraisal Center and Shandong Provincial Cord Blood Bank. The company learned in detail about the storage and application prospects of cells in 5G scenarios, the application of cryogenic medicine, the first case of human cryopreservation in Asia, the technological innovation and industrial functions of cryomedicine in organ transplantation and clinical applications, and virtual anatomical experiments. In this investigation, we had a comprehensive understanding of the industrial layout, cutting-edge technology, R&D and innovation, and achievement transformation of Yinfeng Biological Group in the biomedical field, and highly recognized and praised the achievements of Yinfeng Biological Group.

Yinfeng Biological Group is a high-tech enterprise specializing in technology research and development, medical transformation and clinical research in the biomedical field such as human cells, tissues and organ storage, gene sequencing technology, cell application technology, cryogenic medical technology and health management services. In the past 19 years, Yinfeng Biotech has taken the lead in opening up the health management service industry chain covering the whole life cycle of human beings in the country, with the development vision of "becoming a leading domestic and international first-class health management service provider for the whole life cycle of human beings", and contributing to the service of "Healthy China".
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.